Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Multiple Myeloma Epidemiology Analysis Report Overview
In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma in 2022. The diagnosed incident cases of multiple myeloma are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. In the early stages, MM may not cause any symptoms. Eventually, MM causes a wide range of problems, including persistent bone pain, usually in the back, ribs, or hips, tiredness, and kidney problems.
Multiple Myeloma Market Outlook, 2022-2032 (Diagnosed Incident Cases)
Buy the Full Report for More Insights into the Multiple Myeloma Market Forecast
The multiple myeloma market research report provides a granular forecast growth analysis for both global and regional markets through 2032. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.
| Market Size (2022) | 80,305 Cases |
| AGR (2022-2032) | >1% |
| Forecast Period | 2023 – 2032 |
| Key Countries | · The US
· France · Germany · Spain · Italy · The UK · Japan · Urban China |
| Key Sex Segments | · Men
· Women |
| Key Types | · Symptomatic
· Asymptomatic |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Multiple Myeloma Market Segmentation by Country
The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, Japan, and Urban China. In 2022, the US accounted for more than 36% of the diagnosed incident cases of MM in the 8MM. By 2032, the US will continue to have the highest number of diagnosed incident cases of MM in the 8MM, whereas Spain will have the fewest diagnosed incident cases. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and diagnosed prevalent cases of MM to a certain extent to the moderately rising trend in the incidence of MM in the 8MM, combined with underlying demographic changes in the respective markets.
Multiple Myeloma Market Analysis by Country, 2032 (%)
Buy the Full Report for More Country Insights into the Multiple Myeloma Market
Multiple Myeloma Market Segmentation by Sex
Based on sex, the multiple myeloma market can be segmented into men and women. In 2022, the number of diagnosed incident cases of multiple myeloma was higher in men in the 8MM combined. Among the 8MM, the UK had the largest difference in the diagnosed incident cases of MM between men and women.
Multiple Myeloma Market Analysis by Sex, 2022 (%)
Buy the Full Report for More Sex Insights into the Multiple Myeloma Market
Multiple Myeloma Market Segmentation by Type
Based on type, the multiple myeloma market can be segmented into symptomatic and asymptomatic. In the 8MM in 2022, symptomatic MM contributed the major proportion.
Multiple Myeloma Market Analysis by Type, 2022 (%)
Buy the Full Report for More Type Insights into the Multiple Myeloma Market
Segments Covered in the Report
Multiple Myeloma Market Country Outlook (Diagnosed Incident Cases, 2022-2032)
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
- Urban China
Multiple Myeloma Market Sex Outlook (Diagnosed Incident Cases, 2022-2032)
- Men
- Women
Scope
- This report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for MM in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
- The report includes a 10-year epidemiology forecast for the diagnosed incident and diagnosed prevalent cases of MM.
- The diagnosed incident cases of MM are segmented by age (18 years and older), by sex, by type (asymptomatic and symptomatic), by stage at diagnosis (R-ISS stage I, R-ISS stage II, and R-ISS stage III), by stem cell transplant (SCT) eligibility (eligible and ineligible), and by genetic and surface markers. The diagnosed prevalent cases of MM are segmented sex, by stage at diagnosis (R-ISS stage I, R-ISS stage II, and R-ISS stage III), and by genetic and surface markers [t(4;14)(p16;q32), t(14;16)(q32;q23), t(14;20) (q32;q12), t(11;14)(q13;q32), and deletion 17p].
- This epidemiology forecast for MM is supported by data obtained from peer-reviewed articles and population-based studies.
- The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of MM across these markets.
Reasons to Buy
The multiple myeloma epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global MM market.
- Quantify patient populations in the global MM market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MM therapeutics in each of the markets covered
Table of Contents
Table
Figures
Frequently asked questions
-
How many diagnosed incident cases of multiple myeloma were seen in the 8MM in 2022?
In 2022, there were 80,305 diagnosed incident cases of multiple myeloma in the 8MM.
-
What is the growth rate of the multiple myeloma market?
The diagnosed incident cases of multiple myeloma are expected to register an AGR of more than 1% during 2022-2032.
-
Which was the leading sex segment in the multiple myeloma market in 2022?
In 2022, the number of diagnosed prevalent cases of multiple myeloma was higher in men in the 8MM combined.
-
Which was the leading type in the multiple myeloma market in 2022?
In the 8MM in 2022, symptomatic MM contributed the major proportion.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Multiple Myeloma (Kahler Disease) reports



